

## Classification of Advanced Bone Cancer Osteosarcoma

Carlo Pangotta\*

Department of Medicine and Health Science, University of Padua, Padua, Italy

\*Corresponding author: Carlo Pangotta, Department of Medicine and Health Science, University of Padua, Padua, Italy, E-mail: pangottacarlo37@yahoo.com

**Received:** 26-Apr-2023, Manuscript No. AOT-23-100364; **Editor assigned:** 28-Apr-2023, PreQC No. AOT-23-100364 (PQ); **Reviewed:** 12-May-2023, QC No. AOT-23-100364; **Revised:** 19-May-2023, Manuscript No. AOT-23-100364 (R); **Published:** 26-May-2023, DOI: 10.4172/aot.1000223

**Citation:** Pangotta C (2023) Classification of Advanced Bone Cancer Osteosarcoma. J Oncol Res Treat. 8:223.

**Copyright:** © 2023 Pangotta C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Description

Osteosarcoma is a rare and aggressive form of cancer that primarily affects the bones, particularly the long bones such as the arms and legs. It is the most common primary malignant bone tumor, predominantly occurring in children, adolescents, and young adults. Osteosarcoma presents numerous challenges in diagnosis, treatment, and long-term management due to its complex nature and potential for metastasis. This article aims to provide a comprehensive overview of osteosarcoma, including its causes, symptoms, diagnosis, treatment options, and ongoing research efforts.

The exact cause of osteosarcoma remains unknown. However, several risk factors have been identified, including genetic predisposition, hereditary conditions (such as Li-Fraumeni syndrome and Rothmund-Thomson syndrome), previous exposure to radiation therapy, and certain genetic mutations such as Tumor Protein 53 (*TP53*) and Retinoblastoma gene 1 (*RBI*) gene mutations. It is important to note that the majority of osteosarcoma cases occur sporadically, without a clear identifiable cause or risk factor. The symptoms of osteosarcoma can vary depending on the location and stage of the tumor. Common signs include persistent bone pain, swelling, limited range of motion, bone fractures, and a palpable mass or lump. As these symptoms are nonspecific, the diagnosis of osteosarcoma requires a combination of imaging studies, such as X-rays, Magnetic Resonance Imaging (MRI), and Computed Tomography (CT) scans, along with a biopsy to confirm the presence of cancerous cells.

Osteosarcoma can be classified into different subtypes based on the appearance of tumor cells under a microscope. The most common subtype is conventional osteosarcoma, while other variants include telangiectatic, high-grade surface, and small-cell osteosarcoma, among others. Staging of osteosarcoma is crucial for determining the extent of cancer spread and planning appropriate treatment strategies. The Enneking or Musculoskeletal Tumor Society (MSTS) staging system is often used, which considers tumor size, presence of metastasis, and whether the tumor is resectable. The treatment of osteosarcoma typically involves a multidisciplinary approach, combining chemotherapy,

surgical resection, and radiation therapy. Neoadjuvant chemotherapy, administered before surgery, aims to shrink the tumor and reduce the risk of metastasis. Surgery involves the removal of the tumor, followed by limb-salvage procedures or amputation in certain cases. Radiation therapy may be used to target residual tumor cells or alleviate symptoms in advanced cases. Advancements in surgical techniques, such as limb-sparing surgeries and reconstructive procedures, have significantly improved the quality of life for osteosarcoma survivors.

The prognosis for osteosarcoma has improved over the years, with survival rates ranging from 60% to 80%. However, the prognosis is highly dependent on various factors, including the tumor's size, location, response to treatment, and the presence of metastasis. Early diagnosis and prompt initiation of treatment play a critical role in improving outcomes. Long-term management involves regular follow-up visits, monitoring for recurrence or metastasis, and supportive care to manage treatment-related side effects. Continued research efforts are focused on improving the understanding of osteosarcoma biology, identifying novel therapeutic targets, and developing more effective treatment strategies. Researchers are exploring the use of targeted therapies, immunotherapies, and combination treatments to enhance treatment outcomes.

### Conclusion

Despite advances in treatment, osteosarcoma shows significant challenges. The disease can metastasize to other parts of the body, particularly the lungs, which can complicate treatment and decrease survival rates. Additionally, the aggressive nature of osteosarcoma and its resistance to conventional therapies can limit treatment options. The prognosis varies depending on factors such as the extent of the disease, response to treatment, and the patient's age. Prompt diagnosis and early intervention improve the chances of successful outcomes. Osteosarcoma research is focused on enhancing treatment strategies and understanding the underlying biology of the disease. Advances in targeted therapies, immunotherapies, and personalized medicine hold promise for improving outcomes and reducing side effects. Clinical trials are being conducted to evaluate novel treatment approaches and identify new biomarkers that can aid in early diagnosis and prognosis.